Up a level
Export as [feed] Atom [feed] RSS 1.0 [feed] RSS 2.0
Group by: Item Type | Date | No Grouping
Jump to: 2017 | 2016 | 2014
Number of items: 6.

2017

Gass, A., Wurfel, J., Kompan, I., Gregori, J., Ziemssen, T., Limmroth, V., Bayas, A., Haas, J., Linker, R., Maeurer, M., Stangel, M., Tackenberg, B., Meergans, M., Harlin, O. and Hartung, H-P (2017). TRUST-Study: Methods of an Optional MRI-Safety Surveillance for Progressive Multifocal Leukoencephalopathy (PML) in Relapsing-Remitting Multiple Sclerosis Patients Treated with Natalizumab. Mult. Scler. J., 23 (2). S. 338 - 339. LONDON: SAGE PUBLICATIONS LTD. ISSN 1477-0970

Hartung, H-P., Gass, A., Wuerfel, J., Bayas, A., Tackenberg, B., Limmroth, V., Linker, R., Maeurer, M., Haas, J., Stangel, M. and Ziemssen, T. (2017). TRUST - evaluation of baseline data to investigate an integrated approach for optimised patient management in multiple sclerosis patients treated with natalizumab. Mult. Scler. J., 23. S. 905 - 907. LONDON: SAGE PUBLICATIONS LTD. ISSN 1477-0970

Limmroth, V., Haverkamp, W., Dechend, R., Kleiter, I., Wagner, B., Schmidt, S., Lassek, C., Wendt, G. and Ziemssen, T. (2017). First dose effects of fingolimod: final results of an in-depth ECG and Holter study in 6,998 German RRMS patients. Mult. Scler. J., 23. S. 383 - 385. LONDON: SAGE PUBLICATIONS LTD. ISSN 1477-0970

2016

Gass, A., Wurfel, J., Kompan, I., Gregori, J., Ziemssen, T., Limmroth, V., Bayas, A., Haas, J., Linker, R., Maeurer, M., Stangel, M., Tackenberg, B., Meergans, M., Harlin, O. and Hartung, H. -P. (2016). TRUST-Study: methods of an optional MRI-safety surveillance for progressive multifocal leukoencephalopathy (PML) in relapsing remitting multiple sclerosis patients treated with Natalizumab. Mult. Scler. J., 22. S. 652 - 654. LONDON: SAGE PUBLICATIONS LTD. ISSN 1477-0970

Limmroth, V., Haverkamp, W., Dechend, R., Lang, M., Haas, J., Wagner, B., Richter, S., Schieb, H., Wendt, G. and Ziemssen, T. (2016). First dose effects of fingolimod: in depth electrocardiographic analysis of over 4.700 patients confirms first dose observation is usually uneventful. Mult. Scler. J., 22. S. 356 - 357. LONDON: SAGE PUBLICATIONS LTD. ISSN 1477-0970

2014

Hartung, H-P, Ziemssen, T., Bayas, A., Tackenberg, B., Wuerfel, J., Limmroth, V., Linker, R., Maeurer, M., Haas, J., Stangel, M., Harlin, O., Winterstein, C., Meergans, M., Wernsdoerfer, C. and Gass, A. (2014). TRUST study design-a study to evaluate an integrated approach for optimized patient management in multiple sclerosis patients treated with natalizumab. Mult. Scler. J., 20. S. 111 - 112. LONDON: SAGE PUBLICATIONS LTD. ISSN 1477-0970

This list was generated on Tue Nov 26 04:16:37 2024 CET.